{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:22:17Z","timestamp":1756570937127,"version":"3.41.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Hypocomplementemia has been reported in patients with rheumatoid arthritis treated with tocilizumab (TCZ), but its long-term consequences are unknown. We assessed the long-term outcome of patients treated with TCZ who developed hypocomplementemia regarding serious bacterial infections or autoimmune diseases (AID).<\/jats:p>\n            <jats:p>The charts of patients treated with TCZ at two rheumatology centers were reviewed retrospectively. Data regarding patients\u2019 age, gender, disease duration, autoantibodies status, previous or concomitant treatments, blood counts, liver enzymes, C3 and C4 levels at baseline and during TCZ treatment, episodes of infections, allergic reactions, and AID were analyzed. Univariate analysis was used to compare patients with low C3, C4 levels versus patients with normal C3, C4 levels. Variables that were statistically significant associated or tended to be associated with low C3 or C4 were included in multiple variable logistic regression.<\/jats:p>\n            <jats:p>Of 132 patients treated with TCZ, 108 had serial measurements of serum complement concentration. Thirty-three (30%) patients developed low C4 levels and 23 (21%) had also low C3. Mean TCZ treatment period was 4.9\u200ayears (range, 1\u201314\u200ayears). All patients had normal complement levels at baseline. Leukopenia occurred in 18 (16.7%) patients, 14 of whom (77%) had low complement. Persistent leukopenia was observed in 8% and 5.3% of patients with normal C3 and C4 levels, respectively, as opposed to 47% and 42% of patients with low C3 or low C4, respectively. Low C3, C4 levels correlated with prolonged TCZ treatment retention time and effectiveness. There were no serious bacterial infections or new onset AID.<\/jats:p>\n            <jats:p>Hypocomplementemia during TCZ treatment was accompanied by leukopenia that correlated with treatment duration. Hypocomplementemia was not associated with serious bacterial infections or new onset AID. Decreased complement levels were associated with treatment longevity. The role of monitoring complement level in predicting treatment response or assessing disease activity deserves further investigation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029528","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:07:15Z","timestamp":1655471235000},"page":"e29528","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Hypocomplementemia during tocilizumab treatment"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0395-4171","authenticated-orcid":false,"given":"Amir","family":"Bieber","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Ha\u2019Emek Medical Center, Afula, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doron","family":"Markovits","sequence":"additional","affiliation":[{"name":"B Shine Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel"},{"name":"Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohava","family":"Toledano","sequence":"additional","affiliation":[{"name":"B Shine Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel"},{"name":"Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonit","family":"Tavor","sequence":"additional","affiliation":[{"name":"B Shine Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel"},{"name":"Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reuven","family":"Mader","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Ha\u2019Emek Medical Center, Afula, Israel"},{"name":"Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Balbir-Gurman","sequence":"additional","affiliation":[{"name":"B Shine Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel"},{"name":"Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Braun-Moscovici","sequence":"additional","affiliation":[{"name":"B Shine Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel"},{"name":"Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"R1-20250612","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cytogfr.2012.04.001","article-title":"Plasticity and cross-talk of Interleukin 6-type cytokines","volume":"23","author":"Garbers","year":"2012","journal-title":"Cytokine Growth Factor Rev"},{"key":"R2-20250612","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00430-006-0019-9","article-title":"Interleukin-6 and its receptor: from bench to bedside","volume":"195","author":"Scheller","year":"2006","journal-title":"Med Microbiol Immunol"},{"key":"R3-20250612","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"Il-6 trans-signaling via the soluble IL-6 receptor: importance for the proinflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int J Biol Sci"},{"key":"R4-20250612","first-page":"3375","article-title":"Science in medicine therapeutic strategies for the clinical blockade of IL-6\u200a\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"Cell"},{"key":"R5-20250612","first-page":"147","article-title":"Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation","volume":"7","author":"Baumann","year":"1990","journal-title":"Mol Biol Med"},{"key":"R6-20250612","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.iy.13.040195.001425","article-title":"Transcriptional regulation of complement genes","volume":"13","author":"Volanakis","year":"2003","journal-title":"Annual Rev Immunol"},{"key":"R7-20250612","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0014-5793(89)80476-4","article-title":"Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes","volume":"242","author":"Castell","year":"1989","journal-title":"FEBS Lett"},{"key":"R8-20250612","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"R9-20250612","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"R10-20250612","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"R11-20250612","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","article-title":"Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial","volume":"51","author":"Spiera","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"R12-20250612","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2478\/v10011-009-0016-9","article-title":"Immune complexes and complement in serum and synovial fluid of rheumatoid arthritis patients","volume":"28","author":"Miju\u0161kovi\u0107","year":"2009","journal-title":"J Med Biochem"},{"key":"R13-20250612","first-page":"1049","article-title":"Significance of complement components C1q and C4 bound to circulating immune complexes in juvenile idiopathic arthritis: support for classical complement pathway activation","volume":"29","author":"Gilliam","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"(Suppl 1)","key":"R14-20250612","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1136\/annrheumdis-2020-eular.2591","article-title":"AB0491 Elevated complement 3 indicates disease activity in Takayasu Arteritis","volume":"79","author":"Chen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R15-20250612","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1001\/jama.1976.03270170042025","article-title":"Serum levels of immunoglobulin and complement in giant-cell arteritis","volume":"236","author":"Malmvall","year":"1976","journal-title":"JAMA"},{"key":"R16-20250612","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"(Suppl 2)","key":"R17-20250612","first-page":"734.2\u2013734","article-title":"SAT0213 hypocomplementemia during Tocilizumab treatment for rheumatoid arthritis: long term follow-up results","volume":"74","author":"Braun-Moscovici","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R18-20250612","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s10067-018-3992-7","article-title":"Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients","volume":"37","author":"Romano","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R19-20250612","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R21-20250612","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"R22-20250612","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.1780330811","article-title":"Criteria for the classification of Takayasu arteritis","volume":"33","author":"Arend","year":"1990","journal-title":"Arthritis Rheumatol"},{"key":"R23-20250612","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","article-title":"The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum"},{"key":"R24-20250612","first-page":"2737","article-title":"Classification criteria for systemic sclerosis: an ACR-EULAR Collaborative Initiative","volume":"65","author":"Hoogen","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R25-20250612","first-page":"328","article-title":"Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients","volume":"16","author":"Alarc\u00f3n-Segovia","year":"1989","journal-title":"J Rheumatol"},{"issue":"(Suppl 3)","key":"R26-20250612","first-page":"A452.2\u2013A453","article-title":"FRI0234 Complement depletion in rheumatoid arthritis patients treated with tocilizumab: a marker of clinical efficacy?","volume":"72","author":"Sandri","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R27-20250612","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/cei.12952","article-title":"Production of complement components by cells of the immune system","volume":"188","author":"Lubbers","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"R28-20250612","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/10454411950060020301","article-title":"Complement biosynthesis in the central nervous system","volume":"6","author":"Barnum","year":"1995","journal-title":"Crit Rev Oral Biol Med"},{"key":"R29-20250612","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00011-006-0068-y","article-title":"Human monocyte-derived dendritic cells are a source of several complement proteins","volume":"55","author":"Reis","year":"2006","journal-title":"Inflam Res"},{"key":"R30-20250612","doi-asserted-by":"crossref","first-page":"7780","DOI":"10.18632\/oncotarget.6846","article-title":"Hepatitis B virus X protein binding to hepsin promotes C3 production by inducing IL-6 secretion from hepatocytes","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"R31-20250612","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/07853890701477546","article-title":"Rheumatoid arthritis and the complement system","volume":"39","author":"Okroj","year":"2007","journal-title":"Ann Med"},{"key":"R32-20250612","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/rheumatology\/kes403","article-title":"Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis","volume":"52","author":"Matsuo","year":"2013","journal-title":"Rheumatology (Oxford, England)"},{"key":"R33-20250612","doi-asserted-by":"crossref","first-page":"e000213","DOI":"10.1136\/rmdopen-2015-000213","article-title":"Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab","volume":"2","author":"Rubbert-Roth","year":"2016","journal-title":"RMD Open"},{"key":"R34-20250612","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/rheumatology\/keu035","article-title":"Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo","volume":"53","author":"Wright","year":"2014","journal-title":"Rheumatology (United Kingdom)"},{"key":"R35-20250612","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/eci.12799","article-title":"Effects of tocilizumab on neutrophil function and kinetics","volume":"47","author":"Lok","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"R36-20250612","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: Pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2017","journal-title":"Rheumatology (United Kingdom)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:00:21Z","timestamp":1749754821000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029528"}},"subtitle":["Long-term follow-up results"],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":35,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029528","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"2021-10-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}